Misonidazole neuropathy. A prospective study

B Melgaard; O Køhler; H Sand Hansen; J Overgaard; J Munck-Hansen; O B Paulson

doi:10.1007/BF00163705

Misonidazole neuropathy. A prospective study

B Melgaard, O Køhler, H Sand Hansen, J Overgaard, J Munck-Hansen, O B Paulson

IKM

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

11 Citationer (Scopus)

Abstract

The frequency with which polyneuropathy developed was investigated in patients with cancer of the larynx and pharynx who participated in a double-blind trial of the radiosensitizing drug misonidazole. Fourteen of 36 patients receiving misonidazole (total dose of about 11 g/m2) developed neuropathy, while this occurred in only 2 of 34 patients in the placebo group. Vibration perception threshold increased in all patients who developed neuropathy, but also in 12 (5 misonidazole and 7 placebo treated) without other symptoms or signs of neuropathy. Pharmacokinetic studies of misonidazole revealed a correlation between development of neuropathy and a high 'peak plasma concentration/g misonidazole in each fraction' and especially a high 'area under plasma concentration curve/g misonidazole in each fraction'.

Originalsprog	Engelsk
Tidsskrift	Journal of Neuro-Oncology
Vol/bind	6
Udgave nummer	3
Sider (fra-til)	227-30
Antal sider	4
ISSN	0167-594X
DOI	https://doi.org/10.1007/BF00163705
Status	Udgivet - nov. 1988

Adgang til dokumentet

10.1007/BF00163705

Citationsformater

@article{935cb73dbe5e4f1dbad3f976a2e1f879,

title = "Misonidazole neuropathy. A prospective study",

abstract = "The frequency with which polyneuropathy developed was investigated in patients with cancer of the larynx and pharynx who participated in a double-blind trial of the radiosensitizing drug misonidazole. Fourteen of 36 patients receiving misonidazole (total dose of about 11 g/m2) developed neuropathy, while this occurred in only 2 of 34 patients in the placebo group. Vibration perception threshold increased in all patients who developed neuropathy, but also in 12 (5 misonidazole and 7 placebo treated) without other symptoms or signs of neuropathy. Pharmacokinetic studies of misonidazole revealed a correlation between development of neuropathy and a high 'peak plasma concentration/g misonidazole in each fraction' and especially a high 'area under plasma concentration curve/g misonidazole in each fraction'.",

keywords = "Adult, Aged, Aged, 80 and over, Clinical Trials as Topic, Double-Blind Method, Female, Humans, Laryngeal Neoplasms/complications, Male, Middle Aged, Misonidazole/adverse effects, Nervous System Diseases/chemically induced, Pharyngeal Neoplasms/complications",

author = "B Melgaard and O K{\o}hler and {Sand Hansen}, H and J Overgaard and J Munck-Hansen and Paulson, {O B}",

year = "1988",

month = nov,

doi = "10.1007/BF00163705",

language = "English",

volume = "6",

pages = "227--30",

journal = "Journal of Neuro-Oncology",

issn = "0167-594X",

publisher = "Springer",

number = "3",

}

TY - JOUR

T1 - Misonidazole neuropathy. A prospective study

AU - Melgaard, B

AU - Køhler, O

AU - Sand Hansen, H

AU - Overgaard, J

AU - Munck-Hansen, J

AU - Paulson, O B

PY - 1988/11

Y1 - 1988/11

N2 - The frequency with which polyneuropathy developed was investigated in patients with cancer of the larynx and pharynx who participated in a double-blind trial of the radiosensitizing drug misonidazole. Fourteen of 36 patients receiving misonidazole (total dose of about 11 g/m2) developed neuropathy, while this occurred in only 2 of 34 patients in the placebo group. Vibration perception threshold increased in all patients who developed neuropathy, but also in 12 (5 misonidazole and 7 placebo treated) without other symptoms or signs of neuropathy. Pharmacokinetic studies of misonidazole revealed a correlation between development of neuropathy and a high 'peak plasma concentration/g misonidazole in each fraction' and especially a high 'area under plasma concentration curve/g misonidazole in each fraction'.

AB - The frequency with which polyneuropathy developed was investigated in patients with cancer of the larynx and pharynx who participated in a double-blind trial of the radiosensitizing drug misonidazole. Fourteen of 36 patients receiving misonidazole (total dose of about 11 g/m2) developed neuropathy, while this occurred in only 2 of 34 patients in the placebo group. Vibration perception threshold increased in all patients who developed neuropathy, but also in 12 (5 misonidazole and 7 placebo treated) without other symptoms or signs of neuropathy. Pharmacokinetic studies of misonidazole revealed a correlation between development of neuropathy and a high 'peak plasma concentration/g misonidazole in each fraction' and especially a high 'area under plasma concentration curve/g misonidazole in each fraction'.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Clinical Trials as Topic

KW - Double-Blind Method

KW - Female

KW - Humans

KW - Laryngeal Neoplasms/complications

KW - Male

KW - Middle Aged

KW - Misonidazole/adverse effects

KW - Nervous System Diseases/chemically induced

KW - Pharyngeal Neoplasms/complications

U2 - 10.1007/BF00163705

DO - 10.1007/BF00163705

M3 - Journal article

C2 - 3066854

VL - 6

SP - 227

EP - 230

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -